Table 5 Safety outcome variables by group and visit
YY-312 group | Placebo group | P-value* | |||
|---|---|---|---|---|---|
n | Mean ± SD | n | Mean ± SD | ||
SBP (mmHg) | |||||
Baseline | 30 | 122.7 ± 12.4 | 30 | 119.9 ± 16.5 | 0.455 |
6 weeks | 24 | 121.2 ± 13.6 | 26 | 118.3 ± 14.5 | 0.470 |
12 weeks | 20 | 119.2 ± 12.1 | 19 | 115.8 ± 15.5 | 0.454 |
DBP (mmHg) | |||||
Baseline | 30 | 77.4 ± 9.5 | 30 | 75.5 ± 9.2 | 0.435 |
6 weeks | 24 | 75.3 ± 8.0 | 26 | 75.0 ± 8.8 | 0.903 |
12 weeks | 20 | 73.1 ± 10.4 | 19 | 74.8 ± 9.1 | 0.583 |
AST (IU/L) | |||||
Baseline | 30 | 21.4 ± 5.5 | 30 | 22.2 ± 5.4 | 0.572 |
6 weeks | 24 | 20.8 ± 8.0 | 26 | 21.1 ± 4.6 | 0.878 |
12 weeks | 20 | 20.3 ± 4.8 | 19 | 22.7 ± 5.8 | 0.154 |
ALT (IU/L) | |||||
Baseline | 30 | 19.4 ± 6.9 | 30 | 22.1 ± 9.7 | 0.223 |
6 weeks | 24 | 19.3 ± 9.6 | 26 | 19.7 ± 7.3 | 0.882 |
12 weeks | 20 | 19.8 ± 10.2 | 19 | 22.9 ± 10.7 | 0.360 |
BUN (mg/dL) | |||||
Baseline | 30 | 11.8 ± 2.7 | 30 | 13.6 ± 4.1 | 0.052 |
6 weeks | 24 | 10.9 ± 2.9 | 26 | 13.1 ± 4.5 | 0.049 |
12 weeks | 20 | 11.3 ± 2.5 | 19 | 12.6 ± 4.2 | 0.217 |
Creatinine (mg/dL) | |||||
Baseline | 30 | 0.7 ± 0.2 | 30 | 0.7 ± 0.1 | 0.663 |
6 weeks | 24 | 0.8 ± 0.1 | 26 | 0.8 ± 0.1 | 0.875 |
12 weeks | 20 | 0.8 ± 0.2 | 19 | 0 8 ± 0.1 | 0.430 |